Literature DB >> 3798404

Effects of oral diltiazem on platelet function: alone and in combination with "low dose" aspirin.

M E Ring, J J Corrigan, P E Fenster.   

Abstract

The effects of 3 days of oral diltiazem, "low dose" aspirin (40 mg/day), and their combination on platelet function was studied in 5 normal subjects. Both drugs inhibited platelet aggregation and ATP release induced by collagen, epinephrine and threshold concentrations of ADP. Aspirin and diltiazem decreased thromboxane A2 generation during ADP induced aggregation by 94 percent and 53 percent respectively, however both agents inhibited aggregation similarly, which suggests that diltiazem's anti-platelet effect was due to mechanisms other than inhibition of thromboxane metabolism alone. Combination therapy resulted in a partially additive inhibitory effect on ADP induced aggregation and thromboxane A2 generation. Two subjects had bleeding times over 15 minutes after receiving combination therapy.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3798404     DOI: 10.1016/0049-3848(86)90013-7

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  4 in total

Review 1.  Diltiazem. A reappraisal of its pharmacological properties and therapeutic use.

Authors:  M M Buckley; S M Grant; K L Goa; D McTavish; E M Sorkin
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

2.  Evaluation of platelet function in aspirin treated patients with CAD.

Authors:  Marlene S Williams; Thomas S Kickler; Dhananjay Vaidya; Ladina S Ng'alla; David E Bush
Journal:  J Thromb Thrombolysis       Date:  2006-06       Impact factor: 2.300

3.  Antiplatelet effects of oral diltiazem, propranolol, and their combination.

Authors:  M E Ring; J J Corrigan; P E Fenster
Journal:  Br J Clin Pharmacol       Date:  1987-11       Impact factor: 4.335

Review 4.  Antihypertensive medications and anemia.

Authors:  Domenic A Sica; Rosemarie Mannino
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-09       Impact factor: 3.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.